We are live on
!
Find out more
KCM
Knoll Capital Management Portfolio holdings
AUM
$180M
1-Year Est. Return
66.11%
This Fund
S&P 500
This Quarter
Est. Return
+0.37%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$96.3M
AUM Growth
+$13.8M
(+17%)
Cap. Flow
+$23.6M
Cap. Flow
% of AUM
24.48%
Top 10 Holdings %
Top 10 Hldgs %
70.51%
Holding
39
New
12
Increased
8
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLT
Applied Therapeutics
APLT
|
+$2.82M |
| 2 |
Kinross Gold
KGC
|
+$2.16M |
| 3 |
Wheaton Precious Metals
WPM
|
+$2.05M |
| 4 |
Equinox Gold
EQX
|
+$2.03M |
| 5 |
SA
Seabridge Gold
SA
|
+$1.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ocular Therapeutix
OCUL
|
+$817K |
| 2 |
Altimmune
ALT
|
+$614K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.32% |
| 2 | Materials | 21.18% |
| 3 | Industrials | 3.38% |
| 4 | Financials | 1.16% |
| 5 | Consumer Staples | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alamos Gold
AGI
$13.9B
| $903K | 0.94% |
+80,000
| New | +$963K |
|
27
Lockheed Martin
LMT
$136B
| $879K | 0.91% |
+2,150
| New | +$954K |
|
28
Royal Gold
RGLD
$19.5B
| $803K | 0.83% |
+7,550
| New | +$858K |
|
29
Pan American Silver
PAAS
$21.6B
| $783K | 0.81% |
+54,085
| New | +$846K |
|
30
OR Royalties Inc
OR
$6.2B
| $732K | 0.76% |
400,000
| – | – |
|
31
Amylyx Pharmaceuticals
AMLX
$2.54B
| $454K | 0.47% |
+24,772
| New | +$524K |
|
|
OMGA
32
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $372K | 0.39% |
173,010
| – | – |
|
|
IRD
33
Opus Genetics
IRD
$302M
| $335K | 0.35% |
100,000
| – | – |
|
|
NEWP
34
New Pacific Metals
NEWP
$1.17B
| $233K | 0.24% |
+131,654
| New | +$308K |
|
35
BioXcel Therapeutics
BTAI
$27.8M
| $152K | 0.16% |
3,750
+1,875
| +100% | +$190K |
|
|
36
Ocular Therapeutix
OCUL
$2.02B
| $1.26K | ﹤0.01% |
400
-199,600
| -100% | -$817K |
|
|
37
Altimmune
ALT
$599M
| – | – |
-173,864
| Closed | -$614K |
|
|
38
CALL
Ocular Therapeutix
OCUL
$2.02B
| – | – |
-95,800
| Closed | -$814K |
|
Similar funds
FBC
AIC
AG
PCA
HIC
FFA
V
RVM
Knoll Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, Knoll Capital Management held 39 positions worth $96.3M, up 17% from $82.5M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Knoll Capital Management deployed $23.6M of net new capital in Q3 2023, opening 12 new positions and adding to 8 existing holdings. Its largest new stake was Kinross Gold: 440,000 shares worth $2.01M.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 79% a quarter earlier, followed by Materials and Industrials.
On the sell side, the largest reduction was Ocular Therapeutix, an estimated $817K trimmed.
- Knoll Capital Management's largest Q3 2023 buy was Kinross Gold: 440,000 shares worth $2.01M.
- Knoll Capital Management added most to Applied Therapeutics in Q3 2023, an estimated $2.82M increase.
- Knoll Capital Management's biggest Q3 2023 reduction was Ocular Therapeutix, cutting an estimated $817K.
- Knoll Capital Management fully exited Altimmune in Q3 2023, selling an estimated $614K.
- Knoll Capital Management's ten largest holdings make up 71% of its $96.3M portfolio in Q3 2023.
- Knoll Capital Management opened 12 new positions and closed 2 in Q3 2023.
- Knoll Capital Management's portfolio value rose 17% quarter-over-quarter to $96.3M.
Based on Knoll Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.